PTPRC and neoplasm: To analyze the gap of trial system in the immune antidrug screening, a synthetic gel formulation was designed as the biofunctional scaffolds with increased tumor formation rate and decreased disease latency.[4a] In our study, the PDA‐modified scaffold was constructed and showed a higher survival rate of CD45+ /CD8+/CD4+ T cells.